FY2022 Q3 Financial and R&D Update

ENHERTU Sales Increase since Launch Steady increase in product sales due to market penetration and additional indications ENHERTU trastuzumab deruxtecan HER2+ BC 2L HER2-low BC US Europe Japan ASCA HER2+ BC 3L HER2+ GC 3L HER2+ BC 3L HER2+ BC 3L HER2+ GC 2L HER2+ BC 3L HER2+ BC 2L HER2+ BC 2L HER2 mutant NSCLC 2L FY2022 Q3 product sales: 60.2 Bn JPY FY2019Q4 FY2020 Q1 FY2020 Q2 FY2020 Q3 FY2020 Q4 FY2021 Q1 FY2021 Q2 FY2021 Q3 FY2021 Q4 FY2022 Q1 FY2022 Q2 FY2022 Q3 Daiichi-Sankyo New indications approved in FY2022 Q3 HER2 low BC HER2+ BC 2L HER2+ GC 2L 12

View entire presentation